Frontier Biotech Completes IPO on Shanghai Stock Exchange

  • 2020-10-28  09:04:39

Nanjing, China, October 28, 2020 -- Frontier Biotechnologies Inc.( Frontier Biotech), a commercial-stage biopharmaceutical company focused on discovering, development, manufacturing, and commercialization of innovative medicines, today announced its completion of the Initial Public Offering (IPO) and listing on Sci-Tech Innovation Board of Shanghai Stock Exchange Limited (Ticker 688221 SH)., with an opening price of 29.11 yuan, an increase of 42% from the initial offering price.


“Successful IPO in domestic capital market is an important milestone in the company's development history and the beginning of a new era. Frontier Biotech will go all out to repay the society with good performance,” said Dong Xie, Founder, Chairman and CSO of Frontier Biotechnologies. “We will continue to uphold innovation and rigor, unswervingly fulfill the obligations of listed companies, be a socially responsible company, and live up to the expectations of investors.”


Frontier Biotech is at a growth acceleration point leveraging significant market opportunities in China and the world. We will continue to strengthen internal R&D and partnering efforts, and global commercialization capabilities of innovative medicines. We fight for life against HIV and other severe infectious diseases internally and with partners, striving for exceptional science, quality and impact, by driving affordability through operational excellence and efficiency.


About Frontier Biotech

Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China striving to bring better medicines to patients globally. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. Our medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. Frontier Biotech's first commercial product was approved by China National Medical Product Administration (NMPA), in May 2018.  Two additional drug candidates are currently undergoing multiple clinical trials in both China and the United States. Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, our long-standing commitment to excellence is in everything we do through the entire development cycle from drug discovery, preclinical research to global clinical development. 

Develop Innovative Therapies to Better Human Lives